Cancer Advisor

Quick Answer Ivermectin and mebendazole are inexpensive generic drugs on their own — so the real question isn't "why does this cost more than the raw chemical," it's "what am I actually getting for that difference." The honest answer is verified potency, correct human dosing, physician screening for contraindications, and a documented chain of custody. Those are the things that go missing with unregulated or veterinary-labeled sources, and they're not minor details — they're the difference between a controlled dose and a guess. Why "Cheaper" Isn't the Same Product It's a fair instinct to look at a compounded prescription and compare it to what the same active ingredients cost elsewhere. But with ivermectin and mebendazole specifically, the price gap usually reflects a difference in what's actually being sold — not just markup. Here's the ...

A critical spotlight on the standout cases from our 760-case compilation — including the most heavily pretreated, "no options left" patients — with an honest look at what the evidence can and cannot tell us. Quick Answer Of the 760 case reports describing antiparasitic drug protocols (fenbendazole, ivermectin, or mebendazole) in patients with cancer, the most clinically notable outcomes fall into three broad categories: (1) rapid complete or near-complete remissions in patients whose disease had progressed despite conventional therapy, (2) imaging-confirmed tumor regressions ranging from 40% to 99%, and (3) patients receiving hospice care or given a prognosis of only weeks to live who survived substantially longer than expected. Only a small fraction of these 760 cases have been published in peer-reviewed journals; the remainder are self-reported anecdotal accounts. Accordingly, these reports should be regarded as hypothesis-generating observations rather than evid...

OneDayMD Editorial Team | Medically reviewed and updated July 2026 Quick Answer Real, registered clinical trials are testing ivermectin and mebendazole in cancer — including a Phase I/II ivermectin + checkpoint-inhibitor trial in metastatic triple-negative breast cancer (NCT05318469) and the ICONIC ivermectin + immunotherapy trial (NCT07487805). Use the searchable tool below, verify current status directly on ClinicalTrials.gov, then contact the study coordinator or ask your oncologist to help you apply. If no trial fits, ask about the expanded access / compassionate use pathway instead of self-sourcing unregulated drugs. Table of Contents Why Clinical Trials Matter for Stage 4 Patients Interactive Trial Finder Tool Current Ivermectin & Mebendazole Trial Registry (2026) How to Search ClinicalTrials.gov Yourself Understanding Eligibility Criteria Expanded Access & Compassionate Use Red Flags: Real Trials vs. Off-Label Telehealth "Protocols" ...

Published: July 2026 | Category: Health Technology & Patient Empowerment Receiving a cancer diagnosis or going through high-stakes screenings can feel overwhelming. Historically, patients relied entirely on the keen eyes of radiologists and pathologists to detect microscopic cellular changes. However, as we move through 2026, a powerful ally has fully integrated into clinical care: AI diagnostic tools in oncology . Artificial intelligence is no longer a futuristic concept confined to research labs. Today, advanced multi-modal AI algorithms work alongside oncologists to spot anomalies faster, predict treatment responses, and minimize human error. If you or a loved one are navigating cancer screenings or treatment this year, understanding how these tools work can provide immense reassurance and empower you to advocate for your health. How AI is Transforming Cancer Detection in 2026 In 2026, medical AI systems have evolved far b...

Quick Answer The Somatic Mutation Theory (SMT) — the model that has guided oncology since the 1970s — holds that cancer starts with random DNA mutations. The 2005 Cancer Genome Atlas Project largely dismantled that idea: no "founding mutation" was ever found, and mutation patterns varied wildly between and within tumors. The Metabolic Theory of Cancer (MTOC) , developed by Dr. Thomas Seyfried at Boston College from decades of mitochondrial research (Otto Warburg, Peter Pedersen), argues that cancer originates from damaged mitochondria forcing cells into fermentation-based energy production (the Warburg effect), with nuclear mutations arising downstream as a consequence, not a cause. This reframing supports combining standard oncology with ketogenic/calorie-restricted metabolic protocols , repurposed drug combinations (e.g., metformin, statins, mebendazole, doxycycline), and cancer-stem-cell-targeting agents — approaches now backed by published trials such as CUSP9...